Single Brain MRI Reveals Accelerated Aging, Dementia Risk
Investigators developed the Dunedin Pace of Aging Calculated from NeuroImaging (DunedinPACNI) to estimate an individual's pace of aging based on brain MRI features such as cortical thickness, surface area, gray matter volume, gray-to-white matter contrast, subcortical volumes, and ventricular sizes.
In a series of studies with more than 50,000 brain MRI scans from people aged 22-98 years across multiple datasets, those whose biological age outpaced their chronological age not only had poorer cognition, faster hippocampal atrophy, and greater dementia risk but also worse general health, including greater frailty, poorer self-reported health, and greater risk for chronic disease and premature death.
While more research on the new tool is needed, investigators said they expect it will be ready for use in clinical practice in a few years.
'Perhaps our boldest expectation is for DunedinPACNI to become part of routine clinical care across the lifespan as an index of faster aging that can help physicians identify patients at risk for later poor health well before symptoms appear and when prevention efforts can be most effective,' Ahmad R. Hariri, PhD, professor of psychology and neuroscience and director, Laboratory of Neurogenetics, Duke University, Durham, North Carolina, told Medscape Medical News .
The study was published online on July 1 in Nature Aging .
Blood-Based Epigenetic Clock
The DunedinPACE-NI tool builds on earlier research from a long-term study that has followed more than 1000 individuals born in Dunedin, New Zealand, in 1972-1973.
The researchers initially used data from this study to develop DunedinPACE, a blood-based epigenetic clock that uses DNA methylation to estimate the rate of aging. While DunedinPACE has shown strong associations with morbidity, brain aging, and more. Itsy, its application is limited to studies where blood samples are available, the researchers noted.
To overcome this limitation, they developed DunedinPACNI, which uses data from a single standard T1-weighted MRI scan to estimate an individual's longitudinal pace of aging — a composite index reflecting physiological decline across cardiovascular, metabolic, immune, renal, and other systems.
The researchers trained DunedinPACNI on MRI data from 860 participants in the Dunedin Study, all scanned at age 45. The model incorporated 315 structural brain features. The algorithm for DunedinPACNI is publicly available to the research community.
Applying this measure to the Alzheimer's Disease Neuroimaging Initiative (ADNI), UK Biobank and BrainLat datasets showed that faster DunedinPACNI scores predicted cognitive impairment, accelerated brain atrophy, and conversion to diagnosed mild cognitive impairment (MCI) or dementia.
For example, in the ADNI sample, individuals deemed to be aging the fastest (top 10%) when they joined the study had a 61% higher risk of progressing to MCI or dementia in the years that followed than average agers. The fast agers also started to have memory problems sooner than those who were found to be aging slower based on DunedinPACNI scores.
In the UK Biobank sample, healthy participants with faster DunedinPACNI at baseline were 14% more likely to be diagnosed with chronic age-related diseases later on.
The fastest agers had an 18% higher risk of being diagnosed with a chronic age-related disease than average agers. Fast aging was also associated with worse cognitive performance, higher frailty, and poorer self-rated health.
Over an average of nearly 10 years of follow-up, those with the fastest DunedinPACNI scores were 41% more likely to die than those who were aging more slowly.
DunedinPACNI also reflects social gradients of health inequities. Faster aging scores were observed in individuals with fewer years of formal education or lower income.
The measure also had similar predictive power for dementia risk and cognitive impairment among Latin American adults in the BrainLat cohort.
'It seems to be capturing something that is reflected in all brains,' Hariri said in a press release.
From Bench to Bedside
'Right now, DunedinPACNI can only tell us if a person is aging faster or slower than others within any given dataset or sample,' Hariri told Medscape Medical News. 'That is, DunedinPACNI is currently a relative measure. It doesn't yet tell us if a person is aging faster or slower than would be expected for any person anywhere in the world who is of the same chronological age. But that is changing quickly.'
Investigators need to develop normative reference charts for DunedinPACNI, similar to what they have done for such measures as height, weight, and BMI, Hariri noted.
'It will take time to analyze the tens of thousands of scans collected across the lifespan necessary to develop these norms, but we've already begun to do this. We are confident that reference norms for DunedinPACNI will be ready within the next year and, subsequently, DunedinPACNI can be adopted in clinical practice within a few years,' Hariri said.
Immediate applications of DunedinPACNI in the research setting include using it as an outcome measure in randomized clinical trials of interventions to slow down aging and as a biomarker of accelerated aging that can help predict the chances that an older person will convert from normal cognitive functioning to MCI or from MCI to dementia, Hariri explained.
DunedinPACNI could also be used in clinical trials of AD interventions. This could be as a surrogate outcome measure in younger people decades before they might develop dementia by showing that an intervention slows down aging, which is itself a major risk factor for dementia, Hariri said.
'In older people, DunedinPACNI may be useful as a screening tool to either reduce heterogeneity in the sample by enrolling people all aging at about the same rate or excluding people for are aging faster than others and who may be at increased risk for unintended side effects of treatment including amyloid related imaging abnormalities (ARIAs),' Hariri added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
an hour ago
- Forbes
Music Is The Overlooked Biohacking Tool That Rewires Your Brain
What started as a fringe experiment with 'smart drugs' and cryotherapy, better known as biohacking, is now a $24 billion movement in the making. Grand View Research projects it will surpass $69 billion by 2030 as consumers invest in everything from continuous glucose monitors to cold plunges. The pursuit of performance and longevity has gone mainstream. Yet in the rush to track, measure and optimize, one tool has been hiding in plain sight: music. Not just background playlists or motivational anthems, but music engineered to directly shape neural activity. Breakthroughs in auditory neuroscience reveal that sound can biohack the brain's rhythms, unlocking altered states for focus, relaxation, sleep and beyond. Unlike supplements or extreme therapies, it requires no extra time, no pills and no pain. Kevin Woods, Ph.D., a Harvard-trained auditory neuroscientist working with explains how sound can tune the brain's electrical patterns through a process called entrainment. 'There's a process called entrainment by which the rhythms in the world are reflected in the brain,' Dr. Woods says. 'When you deliver to somebody a sound that is rhythmic and repetitive, you get activity in the brain at that rate, but it spreads from the auditory cortex throughout the brain all the way into frontal areas that control cognition.' That spread matters because brain rhythms govern essential functions. Fast rhythms coordinate attention. Slow rhythms shape sleep. By deliberately embedding modulation patterns into music, researchers guide these rhythms, and with them, behavior. Dr. Woods notes, 'When you go and measure somebody's behavior, somebody's ability to do a focused task, it turns out you get a boost there as well. And they've shown similar things with sleep, with meditation, all at different brainwave frequencies.' The ADHD Advantage The impact has been especially notable for people with ADHD. Dr. Woods' team has published research in Nature Communications Biology showing that engineered music produces measurable changes in ADHD brains. For CEO Dan Clark, the science is personal. 'As someone with ADHD who dropped out of high school, I'd tried everything to improve my focus: Adderall, nootropics, meditation. Nothing worked consistently. Then I tried What felt like 45 minutes was actually four hours of deep productivity. I became so obsessed, I wanted to work for the company.' Clark says the power lies in built-in stimulation. 'The secret isn't removing distractions, but adding structured stimulation so you don't get bored while trying to focus. It makes the work you're already doing take up a bigger share of your mind by boosting your engagement and enjoyment.' From Playlists To Flow That built-in stimulation is exactly what resonated with Kyra Klopp, vice president of media and digital marketing at Runyon Saltzman Inc. Before she relied on lo-fi or ADHD-themed playlists to get through work, but the inconsistency was draining, especially when there was the urge to skip songs based on lyrics or tempo. During her trial, she noticed a shift. 'I wasn't spending mental energy trying to get into flow anymore. Before, there was this whole ritual of finding the right playlist, adjusting volume, maybe switching songs if they weren't hitting right. With it just became 'headphones on and go.' It freed up that cognitive bandwidth I didn't even realize I was using just to manage my focus environment.' The breakthrough moment came when she powered through a three-hour block of dense documents and tedious admin tasks. The music became less about the noise and more about maintaining the thread of concentration. Performance On Demand For both executives and employees, the promise is simple: fewer wasted hours, more sustained energy. Clark frames it as a matter of workplace equity. 'When productivity tools only work for neurotypical brains, 15-20% of your workforce has to figure it out on their own. That's not just unfair, it's a bad investment. Companies lose access to the innovative thinking, creative problem-solving and hyperfocus abilities that neurodivergent minds bring to the table.' Dr. Woods notes that sound stands apart from other biohacking tools due to its practicality. 'If I tell you I'm going to produce positive impacts on your body, but you don't have to do anything, and you don't have to pop a pill, that becomes very attractive,' he says. 'Hearing is a particularly good one, because it doesn't get in the way of other things you need to do. You're typing, reading, working, but your ears are open.' As the biohacking industry pursues increasingly extreme interventions, music may turn out to be the simplest—and most effective—hack of all. 'You're listening to music anyway,' Dr. Woods concludes. 'How about you just listen to slightly modified music, and it will provide these benefits.'
Yahoo
2 hours ago
- Yahoo
Anavex Life Pre-Treatment Prevented Cognitive Impairment In Animal Model of Alzheimer's Disease, New Publication Shows
Anavex Life Sciences Corp. (NASDAQ:AVXL) reported a peer-reviewed publication in the journal Neuroscience Letters on Wednesday. The study shows that a pre-treatment with blarcamesine prevented Amyloid beta-induced memory impairment and brain oxidative injury. "This preclinical study is exciting since it clearly demonstrates a preventative effect of blarcamesine in Alzheimer's pathology and potentially might be able to prevent onset of Alzheimer's disease in healthy individuals," said Tangui Maurice, PhD, Research Director at the University of Montpellier, France and author of the placebo-controlled mice developed significant amyloid toxicity in the brains after the toxic Aβ25-35 peptide injection, in animals pre-treated with blarcamesine, significant protection was observed, with less vulnerability to Aβ25-35-induced oxidative stress and less vulnerability to develop learning and memory deficits. The mechanistic confirmation that blarcamesine particularly restores impaired autophagy through SIGMAR1 activation by acting upstream of amyloid and tau pathologies at the molecular level was previously established in vitro and in vivo. Blarcamesine studies demonstrated the effect of enhanced autophagic flux in human cells and in C. elegans, as well as increased proteostasis capacity and ability to promote autophagosome biogenesis, autophagic cargo reception, and lysosome fusion. SIGMAR1 has emerged as a key therapeutic target in the treatment of neurodegenerative disorders. Its activation enhances autophagy, facilitating the degradation of amyloid-beta precursor protein (APP) and helping to normalize Aβ production. SIGMAR1 activation supports neurogenesis, mitigates oxidative stress by reducing reactive oxygen species (ROS), suppresses neuroinflammatory responses, and alleviates Aβ-induced toxicity. It also plays a critical role in maintaining endoplasmic reticulum (ER) integrity and modulating intracellular calcium signaling. Collectively, these effects contribute to restoring cellular homeostasis, rebalancing neural function, and promoting neuroplasticity. In April, Anavex Life Sciences announced that over three years of continuous treatment with blarcamesine (ANAVEX 2-73) demonstrated significant amelioration of clinical decline, showing continued clinical and meaningful benefit for early Alzheimer's disease patients. Price Action: AVXL stock is up 1.59% at $9.59 during the premarket session at the last check on Wednesday. Read Next:Photo via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Anavex Life Pre-Treatment Prevented Cognitive Impairment In Animal Model of Alzheimer's Disease, New Publication Shows originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
4 hours ago
- New York Post
I had breast cancer at 24 — now I'm already going through menopause
Mood swings. Hot flashes. Night sweats. They're symptoms most women expect in middle age, not when you're barely old enough to rent a car. But Alexis Klimpl was just 25 when the brutal reality of premature menopause struck. A year ago, though, she faced an even tougher battle — and was unsure if she'd live long enough to go through the so-called 'change of life' at all. Advertisement 9 Alexis Klimpl is a publicist based in San Diego, Calif. Courtesy Alexis Klimpl A lump and a life-changing call Lying in bed at home in San Diego one night last July, Klimpl reached down to scratch an itch — but her hand froze as her fingers brushed against a small, hard lump on her right breast. 'I shot up and looked over at my boyfriend, and my face just dropped,' she told The Post. Advertisement Her mind ran through the possibilities: fibrous tissue, a cyst, maybe even a benign tumor. But lurking in the back of her mind was a thought she couldn't shake: breast cancer. In 2025, the American Cancer Society estimates that 316,950 women in the US will be diagnosed with the disease — yet only a small fraction of these cases occur in women under 45. Even fewer are as young as Klimpl, then just 24. Her thoughts quickly turned to her father, who had died of bile duct cancer at 67. 9 Klimpl credits the support of her family and friends as a major bright spot in her cancer journey. Courtesy Alexis Klimpl Advertisement But Klimpl didn't get it checked out immediately. Days later, she left for a three-week surfing trip to Indonesia to chase waves her father had introduced her to as a young girl. 'I wasn't going to cancel that for anything,' she said. The lump was the size of a Skittle when she left. When she returned less than a month later, it had grown to the size of a grape. 'We always think that we're going to be young and healthy forever, and that's just not the case.' Alexis Klimpl Advertisement Alarmed, her doctor ordered a mammogram and biopsy. She then got a call asking her to come in the next day to discuss the results, sending her into a panic. 'I was spiraling,' she recalled. 'What if it's terminal? What if it's growing faster than we can start chemo? What am I going to do about work? Oh god, am I going to be able to have kids one day?' The next morning, her worst fears were confirmed: The lump was Stage 1 triple positive breast cancer. Two weeks later, an MRI showed it had advanced to Stage 2. 9 Concerned about chemotherapy negatively affecting her fertility, Klimpl froze her eggs before starting treatments. Courtesy Alexis Klimpl Facing the future Doctors warned her that chemotherapy could threatened her ability to have children naturally — and hormone injections to stave off future cancer could send her into early menopause — so she met with a fertility specialist who recommended freezing her eggs. What followed was a 'brutal process' that took over her entire August, what Klimpl calls 'one of the hardest parts of this whole journey.' Even after egg retrieval, she was laid up for two weeks, unable to move from the abdominal soreness. The goal was 20 eggs. Doctors got 36. Coping with chemo Advertisement Eggs frozen, Klimpl, a publicist, began six rounds of chemotherapy. To try to save her hair, she did cold capping, a treatment that cools the scalp to about 37°F, reducing blood flow and making hair follicles less vulnerable to the drugs. 9 Klimpl's chemotherapy treatments were stretched out over the span of three months. Courtesy Alexis Klimpl But the frozen headgear — worn before, during and after infusions — brought its own side effects, including headaches, chills, dizziness and scalp pain. Advertisement 'I remember always thinking, this time I'm going to be strong, but then [the cap] touches you, and like a flip of a switch, you just absolutely lose it in front of a room full of strangers,' she said. 'It was hard seeing people my age going out and having fun, meeting new people. My life was on pause.' Alexis Klimpl She ended up losing about 30% of her hair — and though she wondered if she'd have been better off shaving her head, she knew being bald, on top of everything else, 'probably would have broken me.' The rest of Klimpl's chemo was milder than expected, with fatigue, body aches and a rash — though the queasiness tested her. Advertisement 9 Cold capping, also known as scalp cooling, helped Klimpl preserve most of her hair while going through chemotherapy. Courtesy Alexis Klimpl 'This nausea was in my bones,' Klimpl recalled. 'I felt it all over my body. It was always there, every single day, for 4½ months.' But the hardest part was being cut off from the ocean — her main source of stress relief — since the salt water could interfere with her cold cap treatments. Advertisement 'My dad was the person who taught me how to surf, and that's how I've always felt most connected to him, so it was pretty emotionally dark for me,' Klimpl said. She also felt isolated. The young survivor group at her hospital mostly included women in their 40s and 50s, many married with kids. 'It was hard seeing people my age going out and having fun, meeting new people,' she said. 'My life was on pause.' 9 Klimpl is a lifelong surfer, and the hope of returning to the ocean kept her motivated through her treatments. Courtesy Alexis Klimpl Surgery, sacrifice and survival Klimpl finished chemotherapy in December. Her tumor had shrunk significantly. Soon after, she faced a tough series of surgeries: tumor removal in late January, a double mastectomy a week later and breast reconstruction in May. The decision to remove both breasts wasn't easy. 'If you get a double, you lose feeling in all of your chest and you can't breastfeed your kid,' Klimpl said. Still, the fear of recurrence lingered. 9 By freezing her eggs before going through chemotherapy, Klimpl hopes to have children naturally in the future. 'My turning point was realizing I needed to do this for myself,' she said. 'Not for the kid I don't even have yet.' Right before her second surgery, as anesthesia took hold, her surgeon told her she was in remission. Hormones and hardships Over the next year, Klimpl will get hormone infusions to lower the risk of cancer returning. For the following decade, she'll take a daily pill that stops her ovaries from producing estrogen to reduce the chance of recurrence even further. 9 Klimpl's loved ones rallied around her at diagnosis and came together to celebrate her remission. Courtesy Alexis Klimpl The treatment pushed her into menopause decades early, bringing a host of uncomfortable symptoms. 'I have hot flashes, like, 20 times throughout the day,' she said, noting that she also struggles with insomnia, joint pain, vaginal dryness and mood swings. 'I'm depressed one day, I'm over the moon the next, and then I'm just numb,' Klimpl said. Strength in struggle Despite everything, Klimpl is holding onto hope for the future. 9 Klimpl was able to return to the ocean in July 2025 — roughly a year after her cancer diagnosis. 'I know I've always been a really strong person because of what I've gone through, but this has taught me that the sky is limitless with what I can do,' Klimpl said. It also shifted her perspective on life itself. 'We always think that we're going to be young and healthy forever, and that's just not the case,' she added. Before her diagnosis, her mom would tell her 'I love you' countless times a day. While she appreciated the affection, she admitted it could sometimes feel a bit much — especially when the messages popped up during work hours. 'She'd always say, 'You never know when the last time is going to be,' and I would always get mad at her for saying that,' Klimpl remembered. 'But now I'm like, damn, she knew all along.'
